{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:20Z","timestamp":1793317880476,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10579-y","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:37:16Z","timestamp":1765348636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of oral semaglutide on cardiovascular events in patients with type 2 diabetes: review of results from the SOUL trial"],"prefix":"10.1007","volume":"31","author":[{"given":"Katy S.","family":"Lehenbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"10579_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2023) 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care 47:S179\u2013S218","DOI":"10.2337\/dc24-S010"},{"key":"10579_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121","journal-title":"N Engl J Med"},{"issue":"10489","key":"10579_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca MP, Catarig A-M, Houlind K et al (2025) Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405(10489):1580\u20131593","journal-title":"Lancet"},{"key":"10579_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844","journal-title":"N Engl J Med"},{"key":"10579_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084","journal-title":"N Engl J Med"},{"key":"10579_CR6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"N Kosiborod Mikhail","year":"2024","unstructured":"Kosiborod Mikhail N, Mark P, Borlaug Barry C (2024) Semaglutide in patients with Obesity-Related heart failure and type 2 diabetes. N Engl J Med 390:1394\u20131407","journal-title":"N Engl J Med"},{"key":"10579_CR7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232","journal-title":"N Engl J Med"},{"key":"10579_CR8","doi-asserted-by":"publisher","first-page":"645507","DOI":"10.3389\/fendo.2021.645507","volume":"12","author":"B Gallwitz","year":"2021","unstructured":"Gallwitz B, Giorgino F (2021) Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne) 12:645507","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10579_CR9","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1111\/dom.13353","volume":"20","author":"B Ahr\u00e9n","year":"2018","unstructured":"Ahr\u00e9n B, Atkin SL, Charpentier G et al (2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or Gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab 20:2210\u20132219","journal-title":"Diabetes Obes Metab"},{"key":"10579_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841\u2013851","journal-title":"N Engl J Med"},{"key":"10579_CR11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL et al (2025) Oral semaglutide and cardiovascular outcomes in High-Risk type 2 diabetes. N Engl J Med 392:2001\u20132012","journal-title":"N Engl J Med"},{"key":"10579_CR12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JFE et al (2025) Oral semaglutide and cardiovascular outcomes in people with type 2 Diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation 151:1639\u20131650","journal-title":"Circulation"},{"key":"10579_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of Glucose-Lowering drugs for type 2 diabetes: A systematic review and network Meta-analysis. Ann Intern Med 173:278\u2013286","journal-title":"Ann Intern Med"},{"key":"10579_CR14","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","volume":"60","author":"RV Overgaard","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ (2021) Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical Pharmacology trials. Clin Pharmacokinet 60:1335\u20131348","journal-title":"Clin Pharmacokinet"},{"key":"10579_CR15","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire DK, Busui RP, Deanfield J et al (2023) Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab 25:1932\u20131941","journal-title":"Diabetes Obes Metab"},{"key":"10579_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, Do Vale RD et al (2023) Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402:705\u2013719","journal-title":"Lancet"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10579-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10579-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10579-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:37:17Z","timestamp":1765348637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10579-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10579"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10579-y","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AN has served as a consultant or as a speaker for Amgen, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Pfizer and VAXXINITY. SN has received grants and\/or speakers\u2019 fees from Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, AMGEN, Menarini. AS has received grants and\/or speakers\u2019 fees and\/or advisory board fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Galaxo Smith Kline, Janssen, Novartis, Novo Nordisk and RACE Oncology. He is supported by the National Heart Foundation of Australia Future Leader Fellowship (Award ID: 106025). JH has served as a consultant for Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}